Hubert de Boysson1, Nicolas Aide2, Eric Liozon3, Marc Lambert4, Jean-Jacques Parienti5, Jacques Monteil6, Damien Huglo7, Boris Bienvenu8, Alain Manrique9, Achille Aouba10. 1. Department of Internal Medicine, Caen University Hospital, France; University of Caen - Basse Normandie, Caen, France. Electronic address: deboysson-h@chu-caen.fr. 2. Department of Nuclear Medicine, Caen University Hospital, France; INSERM U1086 «ANTICIPE», BioTICLA, François Baclesse Cancer Centre, Caen, France. Electronic address: aide-n@chu-caen.fr. 3. Department of Internal Medicine, Limoges University Hospital, Limoges, France. Electronic address: eric.liozon@chu-limoges.fr. 4. Department of Internal Medicine, Lille University Hospital, France. Electronic address: marc.lambert@chru-lille.fr. 5. Biostatistics and Clinical Research Unit, Caen University Hospital, France. Electronic address: parienti-jj@chu-caen.fr. 6. Department of Nuclear Medicine, Limoges University Hospital, France. Electronic address: Jacques.monteil@chu-limoges.fr. 7. Department of Nuclear Medicine, Lille University Hospital, France. Electronic address: Damien.huglo@chru-lille.fr. 8. Department of Internal Medicine, Caen University Hospital, France; University of Caen - Basse Normandie, Caen, France. Electronic address: bbienvenu@hopital-saint-joseph.fr. 9. Department of Nuclear Medicine, Caen University Hospital, France; Normandie Université EA4650, Caen, France. Electronic address: manrique@cyceron.fr. 10. Department of Internal Medicine, Caen University Hospital, France; University of Caen - Basse Normandie, Caen, France. Electronic address: aouba-a@chu-caen.fr.
Abstract
OBJECTIVE: 18F-FDG PET/CT can detect large-vessel involvement in giant-cell arteritis (GCA) with a good sensitivity. In patients with clinically and biologically controlled disease, we aimed to assess how vascular uptakes evolve on repetitive FDG-PET/CT. PATIENTS AND METHODS: All included patients had to satisfy the 4 following criteria: 1) diagnosis of GCA was retained according to the criteria of the American College of Rheumatology or based on the satisfaction of 2 criteria associated with the demonstration of large-vessel involvement on FDG-PET/CT; 2) all patients had a positive PET/CT that was performed at diagnosis before treatment or within the first 10days of treatment; 3) another FDG-PET/CT was performed after at least 3months of controlled disease without any relapse; 4) patients were followed-up at least for 12months. RESULTS: Twenty-five patients (17 [68%] women, median age: 69 [65-78]) with large-vessel inflammation on a baseline FDG-PET/CT and with repetitive imaging during the period with controlled disease were included and followed-up for 62 [25-95] months. Four repeated procedures revealed total extinction of vascular uptakes at 11.5 [8-12] months after the first FDG-PET/CT. Eight PET/CT revealed decreased numbers of vascular uptakes, and 10 procedures revealed no changes. The 3 remaining procedures indicated worsening of the numbers of vascular uptakes in the absence of relapse. CONCLUSIONS: Our study revealed long-term persistent vascular uptake on repeated FDG-PET/CT in >80% of our GCA patients with large-vessel inflammation and clinical-biological controlled disease. Prospective studies are required to confirm these findings.
OBJECTIVE: 18F-FDG PET/CT can detect large-vessel involvement in giant-cell arteritis (GCA) with a good sensitivity. In patients with clinically and biologically controlled disease, we aimed to assess how vascular uptakes evolve on repetitive FDG-PET/CT. PATIENTS AND METHODS: All included patients had to satisfy the 4 following criteria: 1) diagnosis of GCA was retained according to the criteria of the American College of Rheumatology or based on the satisfaction of 2 criteria associated with the demonstration of large-vessel involvement on FDG-PET/CT; 2) all patients had a positive PET/CT that was performed at diagnosis before treatment or within the first 10days of treatment; 3) another FDG-PET/CT was performed after at least 3months of controlled disease without any relapse; 4) patients were followed-up at least for 12months. RESULTS: Twenty-five patients (17 [68%] women, median age: 69 [65-78]) with large-vessel inflammation on a baseline FDG-PET/CT and with repetitive imaging during the period with controlled disease were included and followed-up for 62 [25-95] months. Four repeated procedures revealed total extinction of vascular uptakes at 11.5 [8-12] months after the first FDG-PET/CT. Eight PET/CT revealed decreased numbers of vascular uptakes, and 10 procedures revealed no changes. The 3 remaining procedures indicated worsening of the numbers of vascular uptakes in the absence of relapse. CONCLUSIONS: Our study revealed long-term persistent vascular uptake on repeated FDG-PET/CT in >80% of our GCA patients with large-vessel inflammation and clinical-biological controlled disease. Prospective studies are required to confirm these findings.
Authors: Idil Esen; William F Jiemy; Yannick van Sleen; Johan Bijzet; Daniel M de Jong; Pieter H Nienhuis; Riemer H J A Slart; Peter Heeringa; Annemieke M H Boots; Elisabeth Brouwer Journal: Rheumatology (Oxford) Date: 2022-07-06 Impact factor: 7.046
Authors: John H Stone; Katie Tuckwell; Sophie Dimonaco; Micki Klearman; Martin Aringer; Daniel Blockmans; Elisabeth Brouwer; Maria C Cid; Bhaskar Dasgupta; Juergen Rech; Carlo Salvarani; Hendrik Schulze-Koops; Georg Schett; Robert Spiera; Sebastian H Unizony; Neil Collinson Journal: Arthritis Rheumatol Date: 2019-07-03 Impact factor: 10.995
Authors: K S M van der Geest; G Treglia; A W J M Glaudemans; E Brouwer; M Sandovici; F Jamar; O Gheysens; R H J A Slart Journal: Eur J Nucl Med Mol Imaging Date: 2021-05-03 Impact factor: 9.236